JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP6727210B2 (ja
JP2018505146A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (https=) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (https=)
EP (1) EP3236991B1 (https=)
JP (1) JP6727210B2 (https=)
KR (1) KR102427527B1 (https=)
CN (1) CN107108709B (https=)
AR (1) AR103246A1 (https=)
AU (1) AU2015371056B2 (https=)
DK (1) DK3236991T3 (https=)
ES (1) ES2742503T3 (https=)
HK (1) HK1246156B (https=)
HR (1) HRP20191292T1 (https=)
HU (1) HUE044783T2 (https=)
IL (1) IL252438B (https=)
MX (1) MX377044B (https=)
MY (1) MY181181A (https=)
PL (1) PL3236991T3 (https=)
PT (1) PT3236991T (https=)
RS (1) RS59154B1 (https=)
RU (1) RU2729011C2 (https=)
SA (1) SA517381673B1 (https=)
SI (1) SI3236991T1 (https=)
TW (2) TWI708781B (https=)
WO (1) WO2016102562A1 (https=)
ZA (1) ZA201703768B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414471A (zh) 2016-05-24 2019-03-01 诺和诺德股份有限公司 Mic-1化合物及其用途
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
JP6852939B2 (ja) * 2017-09-04 2021-03-31 89バイオ リミテッド89Bio Ltd. 変異体fgf−21ペプチドコンジュゲート及びその使用
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4337680A1 (en) 2021-05-11 2024-03-20 Cytoki Pharma ApS Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
US20240376168A1 (en) * 2021-09-08 2024-11-14 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
PE20252745A1 (es) 2023-03-30 2025-12-05 Novo Nordisk As Compuestos de fusion y usos de estos
AR132645A1 (es) * 2023-05-12 2025-07-16 Novo Nordisk As Antagonista de acción prolongada del receptor de la hormona del crecimiento y uso del mismo
TW202511291A (zh) 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗il-6結構域之抗體
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
CN1890371A (zh) 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ アルブミン様物質に結合した新規のglp−1類似物
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101663046B (zh) 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
EP2296690B1 (en) * 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
JP5878757B2 (ja) * 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Fgf21変異体およびその使用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
MX2014002260A (es) * 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
WO2014037373A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
MX383664B (es) * 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.

Similar Documents

Publication Publication Date Title
JP2018505146A5 (https=)
RU2017125050A (ru) Производные fgf21 и их применения
JP2013532644A5 (https=)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2013533227A5 (https=)
JP2016512425A5 (https=)
HRP20201881T1 (hr) Spojevi koji su suagonisti glukagona i glp-1
JP2013543497A5 (https=)
PH12019500074A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
JP2017500289A5 (https=)
JP2017502024A5 (https=)
JP2016500682A5 (https=)
JP2012506402A5 (https=)
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
JP2014224121A5 (https=)
JP2016153410A5 (https=)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
JP2013518115A5 (https=)
WO2012069836A3 (en) Biologically active complex and its preparation
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF PUMP DISEASE
WO2008138348A1 (en) Preparation of complexed lactalbumin